Navigation Links
Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Date:5/15/2012

difficulty swallowing.  By providing a once-daily regimen for patients with moderate to severe Alzheimer's disease, Arimenda will meet the market need for a therapy that has the potential to ease caregiver burden, extend the duration of homecare, and delay the admission of patients to costly skilled nursing facilities.  Arimenda will be investigated in a Phase 3 safety study of up to 300 subjects to be conducted at approximately 50 centers in the United States and rest of the world. 

About Alzheimer's Disease

Alzheimer's disease is a chronic, progressive neurodegenerative condition that afflicts over 50 million patients worldwide including more than 5 million sufferers in the United States. The direct healthcare costs exceed $200 billion driven by moderate to severe patients who require care in nursing facilities and assisted living facility.  Caregiver burden is a second significant economic cost of the disease with 15 million caregivers providing 17 billion hours of unpaid care to dementia patients per year, valued at over $200 billion. The treated population is forecast to increase from the current 2.2 million to nearly 3.5 million by 2020.  

There is no cure on the horizon for Alzheimer's disease or for other diseases that cause dementia. Progression of dementia leads to dependence on caregivers and family, who struggle with managing activities of daily living, behavioral challenges, and complicated dosing regimens of the multiple medications that most dementia patients require. Recent outcome studies have shown that memantine and donepezil combination therapy, as compared to monotherapy, significantly increases the time nursing home admissions and significantly reduces health care costs. Despite these benefits, less than 30% of patients are currently treated with combination therapy. Adamas' Arimenda is specifically designed to address these issues, increasing the access to combination
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
5. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
(Date:4/16/2015)... 16, 2015 Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, announced today that ... Commission an Annual Report on Form 20-F that included ... 2014. An electronic version of Mindray,s Annual Report ... relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
(Date:4/16/2015)... 2015 Mallinckrodt plc (NYSE: MNK ... that it has completed its acquisition of Ikaria, ... billion. The Ikaria acquisition extends Mallinckrodt,s footprint in ... neonatal critical care with INOMAX ® (inhaled ... highly vulnerable patient population. It also accelerates Mallinckrodt,s ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5
... FRANCISCO, Oct. 30 CCBR-SYNARC, the world,s leading provider ... center services to the pharmaceutical and biotechnology industries, announced ... for use in imaging clinical trials. , SYNARC has ... 2004. With the release of the enhanced SynarcConnect(SM) ...
... Inc. announced the re-launch of its changing possibilities ... Web site and a new community on Facebook®. People ... Nordisk is committed to helping this community realize that ... new online resources were created to engage and connect ...
Cached Medicine Technology:CCBR-SYNARC Expands Electronic Data Capture Capabilities 2Novo Nordisk is Changing Possibilities in Hemophilia 2Novo Nordisk is Changing Possibilities in Hemophilia 3
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... Representatives Jim Himes (D-CT) and Ed Royce ... 1849 in congress on April 16, 2015 in an ... with the genetic disease. , The bill, similar ... first to create a federally led and financed initiative ... telangiectasia. This would effectively prevent premature death and disability ...
(Date:4/17/2015)... Most dental patients are not aware ... made overseas by foreign dental laboratories, according to the ... in more than 40 states by their respective state ... Dental Laboratories has created the “What’s In ... about the consequences that could be associated with using ...
(Date:4/17/2015)... 2015 Scientists from the Icahn ... of U.S. and Venezuelan researchers, have discovered the ... among an isolated tribe of Yanomami Amerindians in ... in the Yanomami, previously unexposed to antibiotics or ... that of people living in industrialized countries, and ...
(Date:4/17/2015)... 2015 Compare-autoinsurance.org has released a new ... online auto insurance quotes . , The online ... for their cars. Drivers should always compare multiple car ... insurance market is a competitive one, which means that ... , It is now possible to compare online ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:National Association Urges Transparency in Dental Industry 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:The Best Auto Insurance Quotes Are Available Online! 2
... developed by an immunologist Dr Brendan O'Sullivan of Brisbane, for ... skyrocketing rates// of medicines that is available for diabetes in ... UQ's Centre for Immunology and Cancer Research (CICR) are developing ... in obesity -- a common precursor to diabetes, reports foodconsumer.org. ...
... a million lives owing to treatment costs that very many ... Asia and Africa seem to be at the receiving end. ... coming out with a facility that would enable mass production ... capacity to lower the costs of each dose by 25 ...
... Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' ... patients//, suffering from lung cancer. ,The Managing Director ... tablet taken once a day and has the potential ... patients with locally advanced or metastatic Non-Small Cell Lung ...
... that the ?6.2bn upgrade of the NHS IT system ... magazine said that the group of academics are questioning if ... saying that the plan was under a "constant review" and ... 30,000 GPs in England to almost 300 hospitals by 2012. ...
... methods it ahs been found that survival rates following ... when emergency medical// personnel used a new form of ... Center. ,Cardiocerebral Resuscitation, is how this new approach is ... procedures. , ,In the words of Michael J. ...
... at assuming the role of a doctor but pretty bad ... University// of Technology has revealed that nearly half of all ... almost always higher than it should be. ,Over medication ... of overmedication have risen from 12% in 1987 to 33 ...
Cached Medicine News:Health News:Type 2 Diabetes Could Be Tackled Using Curry Colouring and Fat Mix 2Health News:Paramedics save more lives following unconventional rules 2
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: